Pathfinders in Biopharma
Ein Podcast von RBC Capital Markets
46 Folgen
-
Uncertainty reigns, but opportunity persists for biotech’s 2025
Vom: 7.2.2025 -
Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments
Vom: 22.11.2024 -
Former Investor Who Chose Broadcasting Over Biotech ETFs
Vom: 30.9.2024 -
Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?
Vom: 29.8.2024 -
Shots-on-Goal Licensing Company Aims for Breakthroughs
Vom: 19.7.2024 -
Why Biopharma Needs to Tell Better Stories on Novel Drugs
Vom: 11.7.2024 -
Venture capital velocity: What’s driving renewed momentum in biotech?
Vom: 8.7.2024 -
Pharma Understands Phase One Data – But Does the Market?
Vom: 21.6.2024 -
Davern Capital sees GLP-1 Opportunities Beyond Obesity
Vom: 14.6.2024 -
Betting on Healthcare’s Future Hits – and Misses
Vom: 10.6.2024 -
Innovation and an Aging Population Drive MedTech
Vom: 5.6.2024 -
Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing
Vom: 3.6.2024 -
Biotech with a Mission to Target Unmet Cancer Needs
Vom: 31.5.2024 -
The M&A Pool Set to Accelerate Biotech Innovation
Vom: 3.4.2024 -
How PIPEs finally unblocked biotech’s funding flows
Vom: 29.3.2024 -
Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back
Vom: 7.3.2024 -
Will the Biotech Rebound Run into Pricing Policy Obstacles?
Vom: 27.2.2024 -
Few IPOs but plenty of follow-on for biotech in 2023
Vom: 22.1.2024 -
U.S. Outlook: Will the US economy achieve a soft landing in 2024?
Vom: 29.12.2023 -
Raising Venture Capital: A New Playbook for A New Era in Biotech
Vom: 22.11.2023
Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.
